HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review | Published in Journal of Health Economics and Outcomes Research

Loading [Contrib]/a11y/accessibility-menu.js

Metrics
HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review

Goran Bencina, Elina Petrova, Demet Sönmez, Sonia Matos Pereira, Ioannis Dimitriadis, Stina Salomonsson,

prostate canceranticancer drugspatient accessreimbursement decisionESMO-MCBSHTA

• https://doi.org/10.36469/001c.75208

Pageviews and PDF downloads

Pageviews Downloads

526 all time

Last 7 days Last 30 days Last 90 days All time

Top Countries
US	122
IN	53
GB	47
DE	35
HR	31
ES	27
NL	23
CN	18
JP	16
AT	15